JP2018531622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531622A5 JP2018531622A5 JP2018531307A JP2018531307A JP2018531622A5 JP 2018531622 A5 JP2018531622 A5 JP 2018531622A5 JP 2018531307 A JP2018531307 A JP 2018531307A JP 2018531307 A JP2018531307 A JP 2018531307A JP 2018531622 A5 JP2018531622 A5 JP 2018531622A5
- Authority
- JP
- Japan
- Prior art keywords
- residues
- fusion polypeptide
- seq
- amino acid
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 188
- 229920001184 polypeptide Polymers 0.000 claims description 187
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 187
- 230000004927 fusion Effects 0.000 claims description 152
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 44
- 125000000539 amino acid group Chemical group 0.000 claims description 43
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 102000006382 Ribonucleases Human genes 0.000 claims description 11
- 108010083644 Ribonucleases Proteins 0.000 claims description 11
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 10
- 102000006996 Aryldialkylphosphatase Human genes 0.000 claims description 9
- 108010008184 Aryldialkylphosphatase Proteins 0.000 claims description 9
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims description 8
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 8
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 6
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 238000006471 dimerization reaction Methods 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 101710126783 Acetyl-hydrolase Proteins 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 230000002103 transcriptional effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 35
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 230000007423 decrease Effects 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 5
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000027866 inflammatory disease Diseases 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108010024976 Asparaginase Proteins 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 108010073807 IgG Receptors Proteins 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000033749 Small cell carcinoma of the bladder Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000007710 urinary bladder small cell neuroendocrine carcinoma Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215256P | 2015-09-08 | 2015-09-08 | |
| US62/215,256 | 2015-09-08 | ||
| PCT/US2016/050405 WO2017044424A1 (en) | 2015-09-08 | 2016-09-06 | Apoa-1 fusion polypeptides and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020202324A Division JP7233113B2 (ja) | 2015-09-08 | 2020-12-04 | ＡｐｏＡ－１融合ポリペプチドならびに関連する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018531622A JP2018531622A (ja) | 2018-11-01 |
| JP2018531622A5 true JP2018531622A5 (OSRAM) | 2019-10-10 |
| JP6953020B2 JP6953020B2 (ja) | 2021-10-27 |
Family
ID=56985674
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531307A Active JP6953020B2 (ja) | 2015-09-08 | 2016-09-06 | ＡｐｏＡ−１融合ポリペプチドならびに関連する組成物および方法 |
| JP2020202324A Active JP7233113B2 (ja) | 2015-09-08 | 2020-12-04 | ＡｐｏＡ－１融合ポリペプチドならびに関連する組成物および方法 |
| JP2022078179A Pending JP2022105200A (ja) | 2015-09-08 | 2022-05-11 | ＡｐｏＡ－１融合ポリペプチドならびに関連する組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020202324A Active JP7233113B2 (ja) | 2015-09-08 | 2020-12-04 | ＡｐｏＡ－１融合ポリペプチドならびに関連する組成物および方法 |
| JP2022078179A Pending JP2022105200A (ja) | 2015-09-08 | 2022-05-11 | ＡｐｏＡ－１融合ポリペプチドならびに関連する組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US12331102B2 (OSRAM) |
| EP (1) | EP3328881B1 (OSRAM) |
| JP (3) | JP6953020B2 (OSRAM) |
| KR (1) | KR102440820B1 (OSRAM) |
| CN (1) | CN107969127B (OSRAM) |
| AU (1) | AU2016321146C1 (OSRAM) |
| CA (1) | CA2997263C (OSRAM) |
| DK (1) | DK3328881T3 (OSRAM) |
| IL (1) | IL257302B (OSRAM) |
| WO (1) | WO2017044424A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| AU2019240609B2 (en) * | 2018-10-29 | 2025-12-11 | Consejo Nacional de Investigaciones Científcas Y Técnicas (Conicet) | TGF- ß receptor II isoform, fusion peptide, methods of treatment and methods in vitro |
| JP7316711B2 (ja) * | 2019-08-19 | 2023-07-28 | ナンジン・ノベル・バイオテクノロジー・カンパニー・リミテッド | 脂質代謝を調節する複製腫瘍溶解性アデノウイルス及びその応用 |
| CN110964119A (zh) * | 2019-12-05 | 2020-04-07 | 沣潮医药科技（上海）有限公司 | 抗疟二聚体免疫粘附素、药物组合物和用途 |
| US12180521B2 (en) | 2021-02-19 | 2024-12-31 | Theripion, Inc. | Paraoxonase fusion polypeptides and related compositions and methods |
| CA3254811A1 (en) * | 2022-05-24 | 2023-11-30 | Bio-Trip B.V. | MODIFIED APOLIPOPROTEINS WITH A TARGET BODY FOR LIPID NANOPARTICLES |
| WO2024158816A1 (en) * | 2023-01-23 | 2024-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugates, compositions, and methods for brain delivery |
| WO2024251979A1 (en) * | 2023-06-07 | 2024-12-12 | Universidad Del País Vasco/Euskal Herriko Unibertsitatea | Backpacked-antibody constructs and their uses |
| WO2024259220A1 (en) | 2023-06-15 | 2024-12-19 | Theripion, Inc. | Pon3 and evolved pon1 fusion polypeptides |
| CN118077649B (zh) * | 2024-02-29 | 2024-09-10 | 复旦大学附属中山医院 | 一种免疫检查点抑制剂构建动脉粥样硬化小鼠模型的方法 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK368882A (da) | 1981-08-25 | 1983-02-26 | Alan John Kingsman | Expessions vektorer |
| US4579821A (en) | 1981-11-23 | 1986-04-01 | University Patents, Inc. | Control of DNA sequence transcription |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US4486533A (en) | 1982-09-02 | 1984-12-04 | St. Louis University | Filamentous fungi functional replicating extrachromosomal element |
| US4599311A (en) | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| US4977092A (en) | 1985-06-26 | 1990-12-11 | Amgen | Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4661454A (en) | 1983-02-28 | 1987-04-28 | Collaborative Research, Inc. | GAL1 yeast promoter linked to non galactokinase gene |
| US5139936A (en) | 1983-02-28 | 1992-08-18 | Collaborative Research, Inc. | Use of the GAL1 yeast promoter |
| US4870008A (en) | 1983-08-12 | 1989-09-26 | Chiron Corporation | Secretory expression in eukaryotes |
| US4931373A (en) | 1984-05-25 | 1990-06-05 | Zymogenetics, Inc. | Stable DNA constructs for expression of α-1 antitrypsin |
| US4766073A (en) | 1985-02-25 | 1988-08-23 | Zymogenetics Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| CA1280080C (en) | 1984-12-06 | 1991-02-12 | Jacques Oberto | Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
| US5063154A (en) | 1987-06-24 | 1991-11-05 | Whitehead Institute For Biomedical Research | Pheromone - inducible yeast promoter |
| US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
| US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
| US5162228A (en) | 1988-12-28 | 1992-11-10 | Takeda Chemical Industries, Ltd. | Gylceraldehyde-3-phosphate dehydrogenase gene and promoter |
| US5162222A (en) | 1989-07-07 | 1992-11-10 | Guarino Linda A | Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses |
| US5298418A (en) | 1991-09-16 | 1994-03-29 | Boyce Thompson Institute For Plant Research, Inc. | Cell line isolated from larval midgut tissue of Trichoplusia ni |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| WO1994006463A1 (en) | 1992-09-14 | 1994-03-31 | Pfizer Inc | Immortalized cells and uses therefor |
| AU5670194A (en) | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5795572A (en) | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
| US6258596B1 (en) * | 1995-05-22 | 2001-07-10 | Aventis Pharmaceuticals Products Inc. | Variants of apolipoprotein A-I |
| US5716808A (en) | 1995-11-09 | 1998-02-10 | Zymogenetics, Inc. | Genetic engineering of pichia methanolica |
| US5955349A (en) | 1996-08-26 | 1999-09-21 | Zymogenetics, Inc. | Compositions and methods for producing heterologous polypeptides in Pichia methanolica |
| US5854039A (en) | 1996-07-17 | 1998-12-29 | Zymogenetics, Inc. | Transformation of pichia methanolica |
| US5736383A (en) | 1996-08-26 | 1998-04-07 | Zymogenetics, Inc. | Preparation of Pichia methanolica auxotrophic mutants |
| JP4344136B2 (ja) | 2000-11-10 | 2009-10-14 | エフ・ホフマン−ラ・ロシュ・リミテッド | アポリポタンパク質類似体 |
| US7445802B2 (en) * | 2000-12-26 | 2008-11-04 | Yeda Research And Development Co. Ltd | Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases |
| US20030008373A1 (en) * | 2001-04-17 | 2003-01-09 | Myriad Genetics, Incorporated | APOA1-interacting proteins and use thereof |
| US7217785B2 (en) * | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
| ATE446771T1 (de) | 2001-05-24 | 2009-11-15 | Zymogenetics Inc | Taci-immunoglobulin-fusionsproteine |
| US20030049694A1 (en) * | 2001-09-10 | 2003-03-13 | Chung-Hsiun Wu | Production of fusion proteins and use for identifying binding molecules |
| WO2005018572A2 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| EP1697415A1 (en) | 2003-11-12 | 2006-09-06 | Biogen Idec MA Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2005058938A2 (en) * | 2003-12-15 | 2005-06-30 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
| EP1711610A2 (en) * | 2004-01-28 | 2006-10-18 | Syntonix Pharmaceuticals, Inc. | HETERODIMERIC FOLLICLE STIMULATING HORMONE-Fc (FSH-Fc) FUSION PROTEINS FOR THE TREATMENT OF INFERTILITY |
| US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| EP1888649A2 (en) | 2005-05-09 | 2008-02-20 | GlycArt Biotechnology AG | Antigen binding molecules having modified fc regions and altered binding to fc receptors |
| US7655757B2 (en) | 2005-06-16 | 2010-02-02 | Wisconsin Alumni Research Foundation | Cytotoxic ribonuclease variants |
| WO2007092932A2 (en) * | 2006-02-08 | 2007-08-16 | Targeted Molecular Diagnostics, Llc | Bivalent erbb ligand binding molecules and methods for their preparation and use |
| EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| KR100888022B1 (ko) * | 2006-12-21 | 2009-03-09 | 재단법인 목암생명공학연구소 | 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8Ｆｃ |
| US20110178029A1 (en) * | 2007-09-14 | 2011-07-21 | Ambrx, Inc. | Modified Human Apolipoprotein A-1 and Their Uses |
| BRPI0915093A2 (pt) * | 2008-06-13 | 2015-10-27 | Proyecto Biomedicina Cima Sl | conjugados para a administração de compostos biologicamente ativos |
| US20100098693A1 (en) * | 2008-10-07 | 2010-04-22 | Pardridge William M | Compositions and methods for blood-brain barrier delivery of organophosphatases |
| CN102070717B (zh) * | 2009-11-19 | 2013-04-10 | 东莞太力生物工程有限公司 | 融合蛋白及其制备方法、编码该蛋白的dna序列、表达载体、宿主细胞、含有该蛋白的药物组合物 |
| US9260529B2 (en) | 2010-02-24 | 2016-02-16 | The University Of Washington Through Its Center For Commercialization | Molecules that bind CD180, compositions and methods of use |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| TWI807362B (zh) * | 2010-11-30 | 2023-07-01 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| KR20250037576A (ko) | 2011-04-29 | 2025-03-17 | 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 | 치료적 뉴클레아제 조성물 및 방법 |
| TW201326209A (zh) * | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| MX2014009979A (es) * | 2012-02-29 | 2014-09-08 | Hoffmann La Roche | Metodo para la reduccion del desplazamiento de los marcos de lectura 1->3. |
| AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| US20140120091A1 (en) | 2012-10-31 | 2014-05-01 | University Of Washington Through Its Center For Commercialization | Fusion proteins for therapy of autoimmune and cardiovascular disease |
| JP2016505272A (ja) * | 2013-01-25 | 2016-02-25 | ラゲルフェッド，ジェンス | 高血糖症の治療のためのアポリポタンパク質ａ−ｉ由来ペプチド |
| TR201818871T4 (tr) * | 2013-05-14 | 2019-01-21 | Bayer Cropscience Nv | Lif Üreten Bitkilerde Transgenlerin Geliştirilmiş Seçici Ekspresyonu |
| WO2015066550A1 (en) | 2013-10-31 | 2015-05-07 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
| US20160009776A1 (en) | 2014-07-10 | 2016-01-14 | Bayer Pharma Aktiengesellschaft | Pdgfrbeta-fc fusion proteins and uses thereof |
-
2016
- 2016-09-06 EP EP16770394.1A patent/EP3328881B1/en active Active
- 2016-09-06 AU AU2016321146A patent/AU2016321146C1/en active Active
- 2016-09-06 CN CN201680051589.5A patent/CN107969127B/zh not_active Expired - Fee Related
- 2016-09-06 CA CA2997263A patent/CA2997263C/en active Active
- 2016-09-06 WO PCT/US2016/050405 patent/WO2017044424A1/en not_active Ceased
- 2016-09-06 KR KR1020187009391A patent/KR102440820B1/ko active Active
- 2016-09-06 DK DK16770394.1T patent/DK3328881T3/da active
- 2016-09-06 JP JP2018531307A patent/JP6953020B2/ja active Active
-
2018
- 2018-02-01 IL IL257302A patent/IL257302B/en unknown
- 2018-03-01 US US15/909,314 patent/US12331102B2/en active Active
-
2020
- 2020-12-04 JP JP2020202324A patent/JP7233113B2/ja active Active
-
2021
- 2021-12-03 US US17/542,181 patent/US11472864B2/en active Active
-
2022
- 2022-05-11 JP JP2022078179A patent/JP2022105200A/ja active Pending
- 2022-09-09 US US17/930,761 patent/US20230024372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018531622A5 (OSRAM) | ||
| US20220267476A1 (en) | Multispecific antibody constructs | |
| JP7496091B2 (ja) | 合理的に設計された新規なタンパク質組成物 | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JP2014521313A5 (OSRAM) | ||
| JP2019533989A5 (ja) | 抗ｐｄ−１抗体及びその使用 | |
| IL268620B1 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2013027391A5 (OSRAM) | ||
| JP2019527047A5 (OSRAM) | ||
| JP2018121657A5 (OSRAM) | ||
| JP2014518883A5 (OSRAM) | ||
| HRP20130204T1 (hr) | Monoklonalna protutijela koja se vežu na hgm-csf i medicinski sastavi koji ih sadrže | |
| WO2018220467A1 (en) | Anti-muc18 human immunotoxin and applications thereof | |
| JP2013539369A5 (OSRAM) | ||
| RS56093B1 (sr) | Postupci za identifikovanje antitela sa smanjenom imunogenošću | |
| JP2014511680A5 (OSRAM) | ||
| JP2020530770A5 (OSRAM) | ||
| IL272103B1 (en) | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer | |
| WO2023116817A1 (zh) | 一种免疫球蛋白降解酶IdeE的突变体的用途 | |
| JP2019509735A5 (OSRAM) | ||
| CN106008708A (zh) | 一种人乙型肝炎病毒x蛋白的单克隆抗体及用途 | |
| JP2010279373A5 (OSRAM) | ||
| CN102617734B (zh) | 抗FGF-2抗体Dab-2及其应用 | |
| EP3841126A1 (en) | Novel cancer immunotherapy antibody compositions | |
| CN116887862A (zh) | 人改性crp特异性中和抗体、以及含有该抗体的药物和抗炎剂 |